Abstract
Individuals with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may experience severe life-threatening toxicity when treated with 5-fluorouracil (5-FU). As routine measurement of enzyme activity is not practical in many clinical centres, we have investigated the use of DNA mutation analysis to identify cancer patients with low enzyme levels. We have identified two new mutations at codons 534 and 543 in the DPD cDNA of a patient with low enzyme activity and screened the DNA from 75 colorectal cancer patients for these mutations and the previously reported splice site mutation (Vreken et al, 1996; Wei et al, 1996). In all cases, DPD enzyme activity was also measured. The splice site mutation was detected in a patient (1 out of 72) with low enzyme activity whereas mutations at codons 534 (2 out of 75) and 543 (11 out of 23) were not associated with low enzyme activity. These studies highlight the need to combine DPD genotype and phenotype analysis to identify mutations that result in reduced enzyme activity.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beuzeboc P., Pierga J. Y., Stoppa-Lyonnet D., Etienne M. C., Milano G., Pouillart P. Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. Eur J Cancer. 1996 Feb;32A(2):369–370. doi: 10.1016/0959-8049(95)00573-0. [DOI] [PubMed] [Google Scholar]
- Diasio R. B., Beavers T. L., Carpenter J. T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988 Jan;81(1):47–51. doi: 10.1172/JCI113308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Etienne M. C., Lagrange J. L., Dassonville O., Fleming R., Thyss A., Renée N., Schneider M., Demard F., Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994 Nov;12(11):2248–2253. doi: 10.1200/JCO.1994.12.11.2248. [DOI] [PubMed] [Google Scholar]
- Fleming R. A., Milano G., Thyss A., Etienne M. C., Renée N., Schneider M., Demard F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992 May 15;52(10):2899–2902. [PubMed] [Google Scholar]
- Harris B. E., Carpenter J. T., Diasio R. B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 1991 Aug 1;68(3):499–501. doi: 10.1002/1097-0142(19910801)68:3<499::aid-cncr2820680309>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- Heggie G. D., Sommadossi J. P., Cross D. S., Huster W. J., Diasio R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987 Apr 15;47(8):2203–2206. [PubMed] [Google Scholar]
- Houyau P., Gay C., Chatelut E., Canal P., Roché H., Milano G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst. 1993 Oct 6;85(19):1602–1603. doi: 10.1093/jnci/85.19.1602. [DOI] [PubMed] [Google Scholar]
- Lu Z., Zhang R., Diasio R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993 Nov 15;53(22):5433–5438. [PubMed] [Google Scholar]
- Lyss A. P., Lilenbaum R. C., Harris B. E., Diasio R. B. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest. 1993;11(2):239–240. doi: 10.3109/07357909309024846. [DOI] [PubMed] [Google Scholar]
- McMurrough J., McLeod H. L. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol. 1996 May;41(5):425–427. doi: 10.1046/j.1365-2125.1996.34212.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Milano G., Etienne M. C. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit. 1996 Aug;18(4):335–340. doi: 10.1097/00007691-199608000-00004. [DOI] [PubMed] [Google Scholar]
- Takimoto C. H., Lu Z. H., Zhang R., Liang M. D., Larson L. V., Cantilena L. R., Jr, Grem J. L., Allegra C. J., Diasio R. B., Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996 Mar;2(3):477–481. [PubMed] [Google Scholar]
- Vreken P., Van Kuilenburg A. B., Meinsma R., Smit G. P., Bakker H. D., De Abreu R. A., van Gennip A. H. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis. 1996;19(5):645–654. doi: 10.1007/BF01799841. [DOI] [PubMed] [Google Scholar]
- Wei X., McLeod H. L., McMurrough J., Gonzalez F. J., Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996 Aug 1;98(3):610–615. doi: 10.1172/JCI118830. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yokota H., Fernandez-Salguero P., Furuya H., Lin K., McBride O. W., Podschun B., Schnackerz K. D., Gonzalez F. J. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem. 1994 Sep 16;269(37):23192–23196. [PubMed] [Google Scholar]